Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03483688
Other study ID # CBMG-C2017007
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 6, 2018
Est. completion date January 10, 2020

Study information

Verified date March 2018
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).


Description:

The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date January 10, 2020
Est. primary completion date December 10, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Volunteered to participate in this study and signed informed consent.

- Age 18-70 years old, male or female.

- Relapse or refractory B cell non-Hodgkin's lymphoma ,Histologically diagnosed as DLBCL,follicular lymphoma and Mantle cell lymphoma according to the NCCN. nonHodgkin's lymphoma Clinical Practice Guidelines (2017 Version 1)

1. DLBCL and Follicular Lymphoma (stage ?-?, grade ?b).

1. Progressive disease after the last standard chemotherapy regimens.

2. Stable disease after the last standard chemotherapy regimens(at least 4 cycles of first-line therapy or 2 cycles of later-line therapy).

3. Relapse or progressive disease within 12 months after autologous stem cell transplantation (SCT).

2. Follicular lymphoma (stage ?-?) (grade?-?a)

1. Relapse or progressive disease within 1 year after the last standard chemotherapy regimens(At least 2 combination chemotherapy regimens).

2. Stable disease after the last standard chemotherapy regimens(at least 2 cycles of combination chemotherapy regimens).

3. Mantle cell lymphoma

1. Relapse after 1st CR or persistent disease, and not eligible or appropriate for SCT.

2. Relapse or progressive disease within 1 year after the last chemotherapy regimens(at least 4 cycles of first-line therapy or 2 cycles of later- line therapy).

3. Relapse or progressive disease within 12 months after autologous SCT.

- All subjects must have received anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1).

- At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor = 1.5cm).

- Expected survival = 12 weeks.

- ECOG score 0-1.

- Left ventricular ejection fraction (LVEF) = 50% (detected by echocardiography).

- No active pulmonary infections, normal pulmonary function and oxygen saturation = 92% on room air.

- At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy) prior to leukapheresis.

- No contraindications of leukapheresis.

- Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial.

Exclusion Criteria:

- History of allergy to cellular products.

- Laboratory tests: absolute neutrophil count < 1.0 × 10^9 /L, platelet count < 50×10^9 /L, serum albumin < 30 g/L,serum bilirubin > 1.5 ULN, serum creatinine > ULN, ALT/AST > 3 ULN.

- History of CAR T cell therapy or any other genetically modified T cell therapy.

- Relapse after allogeneic hematopoietic stem cell transplantation.

- Active infections that require treatment (uncomplicated urinary tract infections and bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal treatment are permitted.

- Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired or congenital immune deficiency diseases, including but not limited to HIV infection.

- Class III or IV heart failure according to the NYHA Heart Failure Classifications.

- QT interval prolongation = 450 ms.

- History of epilepsy or other central nervous system disorders.

- Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging.

- History of other primary cancers, with the following exceptions.

1. Excisional non-melanoma (e.g. cutaneous basal cell carcinoma).

2. Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer).

- Autoimmune diseases that require treatment, immune deficiency diseases or other diseases that require immunosuppressive therapy.

- Used of systemic steroids within two weeks (using inhaled steroids is an exception).

- Women who are pregnant or lactating, or who have breeding intent in 6 months.

- Participated in any other clinical trial within three months.

- Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed.

Study Design


Intervention

Biological:
CD19-directed CAR-T cells
CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking Union Medical College Hospital Cellular Biomedicine Group Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary AE Incidence of adverse events (AEs) and serious adverse events (SAEs) 12 weeks
Secondary Overall response rate (ORR) The ORR will be assessed at weeks 4 ,weeks 12 ,months 6 and months 12 12 months
Secondary Duration of remission (DOR) The DOR will be assessed at months 12 12 months
Secondary Progression free survival (PFS) The PFS will be assessed at months 12 12 months
Secondary Overall survival rate(OSR) The OSR will be assessed at weeks 12 ,months 6 and months 12 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT03671018 - A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00992446 - Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Phase 2
Completed NCT03263637 - Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Phase 1
Active, not recruiting NCT02633111 - DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Terminated NCT02151903 - Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL Phase 1/Phase 2
Completed NCT01919619 - Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Phase 2
Terminated NCT01874288 - A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL Phase 1/Phase 2
Completed NCT02847130 - Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Suspended NCT03704714 - Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05053971 - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas Phase 1/Phase 2
Completed NCT03677141 - A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02981914 - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Early Phase 1
Terminated NCT05107856 - PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies Phase 1
Recruiting NCT06191887 - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Phase 1
Active, not recruiting NCT05201248 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma Phase 1
Terminated NCT03195010 - Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Phase 2
Recruiting NCT06052826 - Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study Phase 2
Completed NCT02424968 - CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Phase 2
Recruiting NCT04970901 - A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Phase 1